Lilly Focuses On Ruboxistaurin Retinopathy NDA After Failed Neuropathy Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
Two trials of reboxistaurin (proposed trade name Arxxant) in diabetic peripheral neuropathy fail to demonstrate statistically significant differences in sensory symptom scores.
You may also be interested in...
Lilly Plans To File Arxxant NDA On Strength Of Single Phase III Trial
The company will pursue a diabetic nephropathy indication for the protein kinase C-beta inhibitor following initial submission for diabetic retinopathy.
Lilly Plans To File Arxxant NDA On Strength Of Single Phase III Trial
The company will pursue a diabetic nephropathy indication for the protein kinase C-beta inhibitor following initial submission for diabetic retinopathy.
Lilly's Diabetic Neuropathy Agent Ruboxistaurin Will Be Called Arxxant
Lilly is proposing to market the diabetic peripheral neuropathy agent ruboxistaurin under the trade name Arxxant